NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis

Sarepta Therapeutics, Inc. (SRPT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SRPT

$22.50

−$0.49 (−2.13%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SRPT with… →

SRPT Key Statistics

As of Sep 4, 2026
Trading
Open
$22.58
Previous Close
$22.99
Day's Range
21.98–22.65
52-Week Range
14.68–25.32
Volume
2.96M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.26
Valuation
Market Cap
$2.38B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
8.76
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
−0.09
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.20
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.54
Financials (FY)
Revenue (FY)
$2.20B+15.58%
Net Income (FY)
−$713.41M−403.27%
Profit marginThe share of revenue left as profit after all costs and taxes.
−6.93%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
105.63M
1-Year Return
+21.89%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
3.35M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SRPT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+4.55%
2025−82.30%
2024+26.09%
2023−25.58%
2022+43.90%
2021−47.18%
2020+32.12%
2019+18.24%
2018+96.14%
2017+102.84%
2016 (partial year)+3.82%

As of September 4, 2026.

SRPT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.20B−$713.41M−32.5%
2024$1.90B$235.24M12.4%
2023$1.24B−$535.98M−43.1%
2022$933.01M−$703.49M−75.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.20B$1.36B−$657.77M−$713.41M−32.5%
2024$1.90B$1.58B$218.08M$235.24M12.4%
2023$1.24B$1.09B−$267.82M−$535.98M−43.1%
2022$933.01M$793.02M−$536.20M−$703.49M−75.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SRPT Valuation vs Biotechnology Median

Median of 656 stocks
MetricSRPTBiotechnology medianvs median
P/S ratio1.2015.260.1x the median
Profit margin−6.93%0.00%6.9 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 19 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Sarepta Therapeutics, Inc. (SRPT) carries a market capitalisation of $2.38B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 835 employees.

SRPT last closed at $22.50 on September 4, 2026. That is −$0.49 (−2.13%) against the previous close. The 52-week range on file runs from $14.68 to $25.32. The latest close sits 53.27% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $2.20B. That is +15.58% against the prior fiscal year, when revenue was $1.90B. The same year closed with a net loss of $713.41M. The reported profit margin is −6.93%. That is 6.9 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −1.54.

Across the 4 fiscal years on file, revenue moves from $933.01M in 2022 to $2.20B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 8.76. The PEG ratio, which sets the P/E against expected earnings growth, reads −0.09. The price-to-sales ratio is 1.2. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +21.89%. Measured over 10 years, that is −1.77% a year compounded. The reported beta is 0.26. Annualized volatility over the trailing 10 years is 70.44%.

Growth & Income

The record shows no dividend for SRPT.

2026 is still running; the price is +4.55% year to date. Across the complete calendar years on file, 2017 returned +102.84% and 2025 returned −82.30%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Sarepta Therapeutics, Inc. (SRPT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Sarepta Therapeutics, Inc. SRPT $2.38B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Sarepta Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Visit website →